Scarica l'app Stockscreener
6.72
1.32%
-0.09
Dopo l'orario di chiusura:
6.70
-0.02
-0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
Is BioCryst Pharmaceuticals Inc. stock bottoming outEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com
Has BioCryst Pharmaceuticals Inc. formed a bullish divergenceWeekly Trend Report & Risk Controlled Daily Trade Plans - newser.com
BioCryst Keen To Take Takeda’s HAE Crown With Astria Acquisition - insights.citeline.com
How BioCryst Pharmaceuticals Inc. stock reacts to oil pricesMarket Volume Report & AI Optimized Trading Strategy Guides - newser.com
BioCryst Pharma (BCRX) Reinstated as 'Buy' by TD Cowen with $30 PT | BCRX Stock News - GuruFocus
Orion, Nuburu, And BioCryst Shares All Tumble On Bad News - Finimize
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX - TradingView
BioCryst To Buy Astria: A Calculated Gamble That Is Not Without Risk - Seeking Alpha
Teladoc Health Expands Clarity Platform With Workplace Safety Tool - TradingView
BioCryst Pharma price target raised to $26 from $24 at Cantor Fitzgerald - Investing.com Canada
BCRX: JMP Securities Raises Price Target Amid Market Outperforma - GuruFocus
Needham Maintains BioCryst Pharmaceuticals (BCRX) Buy Recommendation - Nasdaq
JMP Securities Maintains BioCryst Pharmaceuticals (BCRX) Market Outperform Recommendation - Nasdaq
What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackGlobal Markets & Expert Curated Trade Setup Alerts - newser.com
RBC Raises Price Target on BioCryst Pharmaceuticals to $15 From $14, Keeps Outperform Rating - MarketScreener
Astria Therapeutics: Pipeline And Market Potential Post BioCryst Acquisition - Seeking Alpha
BioCryst Pharma (BCRX) Sees Analyst Upgrade with Increased Price Target | BCRX Stock News - GuruFocus
BioCryst to buy Astria Therapeutics for $700m in enterprise value - Pharmaceutical Technology
Will BioCryst Pharmaceuticals Inc. stock maintain growth story2025 Trading Volume Trends & High Accuracy Swing Trade Signals - newser.com
How the Astria Deal Is Shaping the New Story for BioCryst Pharmaceuticals - Yahoo Finance
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS) - WV News
Oppenheimer downgrades Astria Therapeutics stock rating to Perform on BioCryst acquisition - Investing.com Canada
Biocryst Pharmaceuticals stock hits 52-week low at $6.00 By Investing.com - Investing.com Nigeria
BioCryst’s Unexpected Plunge: Market’s Response - timothysykes.com
Low frequency sounds good to Biocryst in $700M Astria HAE buy - BioWorld MedTech
BioCryst stock price target raised to $15 by RBC on HAE acquisition - Investing.com UK
Form 425 Astria Therapeutics, Filed by: BIOCRYST PHARMACEUTICALS INC - StreetInsider
BioCryst Pharma stock price target raised to $15 by Jefferies on Astria acquisition - Investing.com Canada
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play - Stocktwits
BioCryst to Acquire Astria in $700M Deal - USA Herald
Health Care Stocks Make Small Moves As Industry News Rolls In - Finimize
Covington, Sidley Guide $700M BioCryst Allergic Disease Deal - Law360
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' - Benzinga
BioCryst Pharmaceuticals, Inc. agreed to acquire Astria Therapeutics, Inc. for approximately $720 million. - MarketScreener
BioCryst goes ‘all in’ on rare swelling disease with Astria deal - BioPharma Dive
Here’s Why Astria Therapeutics Stock (ATXS) Exploded Today - TipRanks
BioCryst to Acquire Astria Therapeutics in $700 Million Deal - contractpharma.com
BioCryst deepens rare diseases focus with $700 million deal for Astria - Reuters
BioCryst To Acquire Astria Therapeutics - citybiz
Mergers and acquisitions - TradingView
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock? - Yahoo Finance
BioCryst Pharmaceuticals To Acquire Astria In $700 Million Deal - Finimize
ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders - Business Wire
BioCryst to Acquire Astria Therapeutics for $700 Million Includi - GuruFocus
BioCryst Announces Acquisition of Astria Therapeutics (ATXS) at $13.00 Per Share - GuruFocus
BioCryst (BCRX) to Acquire Astria Therapeutics in $700M Deal - GuruFocus
BioCryst To Acquire Astria Therapeutics In $700M Deal - Stocktwits
BioCryst Pharmaceuticals To Acquire Astria Therapeutics In $700 Million Cash-and-Stock Deal - Nasdaq
BioCryst to acquire Astria Therapeutics for $700 million - Investing.com
BioCryst to acquire Astria Therapeutics for $700 million By Investing.com - Investing.com Canada
BioCryst to Acquire Astria in Deal Valued at $700 Million - MarketScreener
BioCryst to buy Astria Therapeutics in $700 million deal - Yahoo Finance
BioCryst To Acquire Astria Therapeutics In $700 Mln Cash-and-Stock Deal - Nasdaq
Astria Therapeutics stock soars after BioCryst acquisition announcement, BioCryst falls By Investing.com - Investing.com Canada
BioCryst Announces Merger with Astria Therapeutics - TipRanks
BioCryst to buy Astria Therapeutics for $13 per share - MSN
BioCryst to acquire Astria Therapeutics, strengthening presence in HAE, transforming growth profile - MarketScreener
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile - The Manila Times
BioCryst Pharmaceuticals Appoints New Board Member - TradingView
0.05%
5.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):